Furthermore, the combination of both AG-120 and AG-221 with standard induction and consolidation therapy is currently being investigated in a phase I study in patients with IDH-mutant AML (NCT02632708), in order to explore both the safety and efficacy of a more targeted and innovative first line approach to AML. This evidence concerns the gene IDH2 and acute myeloid leukemia.